MA47223A - Conjugués polypeptide-antigène avec des acides aminés non naturels - Google Patents

Conjugués polypeptide-antigène avec des acides aminés non naturels

Info

Publication number
MA47223A
MA47223A MA047223A MA47223A MA47223A MA 47223 A MA47223 A MA 47223A MA 047223 A MA047223 A MA 047223A MA 47223 A MA47223 A MA 47223A MA 47223 A MA47223 A MA 47223A
Authority
MA
Morocco
Prior art keywords
polypeptide
amino acids
natural amino
antigen conjugates
conjugates
Prior art date
Application number
MA047223A
Other languages
English (en)
Inventor
Wei Chan
Jeffery Fairman
Jon Heinrichs
Original Assignee
Sutrovax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutrovax Inc filed Critical Sutrovax Inc
Publication of MA47223A publication Critical patent/MA47223A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MA047223A 2016-12-30 2017-12-29 Conjugués polypeptide-antigène avec des acides aminés non naturels MA47223A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662441115P 2016-12-30 2016-12-30
US201762530803P 2017-07-10 2017-07-10
US201762568201P 2017-10-04 2017-10-04
US201762591160P 2017-11-27 2017-11-27

Publications (1)

Publication Number Publication Date
MA47223A true MA47223A (fr) 2019-11-06

Family

ID=62710794

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047223A MA47223A (fr) 2016-12-30 2017-12-29 Conjugués polypeptide-antigène avec des acides aminés non naturels

Country Status (16)

Country Link
US (2) US11998599B2 (fr)
EP (2) EP4588521A3 (fr)
JP (3) JP7186166B2 (fr)
KR (2) KR20240110660A (fr)
CN (2) CN118662649A (fr)
AU (2) AU2017388891C1 (fr)
BR (1) BR112019013475A2 (fr)
CA (1) CA3048981A1 (fr)
DK (1) DK3562503T3 (fr)
ES (1) ES3024474T3 (fr)
IL (2) IL317054A (fr)
MA (1) MA47223A (fr)
MX (2) MX2019007910A (fr)
PH (1) PH12019501552A1 (fr)
WO (1) WO2018126229A2 (fr)
ZA (1) ZA201904307B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325008B1 (fr) * 2015-07-21 2025-09-10 Pfizer Inc. Compositions immunogènes contenant des antigènes saccharidiques capsulaires conjugués, kits comprenant ces compositions et leurs utilisations
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
DK3562503T3 (da) 2016-12-30 2025-05-26 Vaxcyte Inc Polypeptid-antigen-konjugater med ikke-naturlige aminosyrer
WO2019050818A1 (fr) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Procédés de formulation de polysaccharides pneumococciques pour conjugaison à une protéine porteuse
CA3050120A1 (fr) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Amelioration de l'immunogenicite de conjugues de polysaccharide de streptococcus pneumoniae et de proteine
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019070994A1 (fr) * 2017-10-04 2019-04-11 Liffey Biotech Limited Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
WO2020010000A1 (fr) 2018-07-04 2020-01-09 Sutrovax, Inc. Procédés améliorés pour la préparation de conjugués immunogènes
IL279855B2 (en) 2018-07-04 2026-01-01 Vaxcyte Inc Improved immunogenic conjugates
WO2020010016A1 (fr) 2018-07-04 2020-01-09 Sutrovax, Inc. Conjugués immunogènes auto-adjuvés
BR112021005425A2 (pt) * 2018-09-23 2021-06-15 Biological E Limited polissacarídeos capsulares purificados de streptococcus pneumoniae
KR20240169145A (ko) * 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
CN109750055B (zh) 2019-03-13 2022-12-23 南开大学 基于α螺旋把手提高蛋白核酸生物耦合效率的方法
CN114025789A (zh) * 2019-04-02 2022-02-08 Vaxcyte公司 侵入质粒抗原b的经优化的无细胞合成和有关的组合物及使用方法
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
BR112021024491A8 (pt) * 2019-06-05 2023-04-11 Merck Sharp & Dohme Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição
MY207971A (en) * 2019-07-18 2025-03-31 Celltrion Inc Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates
CN112394115A (zh) * 2019-08-19 2021-02-23 鲁南制药集团股份有限公司 一种聚乙二醇化重组粒细胞刺激因子peg俢饰度的检测方法
CN110845587B (zh) * 2019-10-15 2021-06-29 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
WO2021146681A1 (fr) * 2020-01-17 2021-07-22 Inventprise, Llc Vaccins multivalents à streptocoques
TW202136285A (zh) 2020-02-18 2021-10-01 美商Ｖａｘｃｙｔｅ公司 含有多醣-蛋白質結合物之a型鏈球菌免疫原性組合物
CN111533792B (zh) 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
WO2022040266A1 (fr) * 2020-08-19 2022-02-24 Vaxcyte, Inc. Procédés de conjugaison de polysaccharide protéine-support
IL305201A (en) * 2021-02-17 2023-10-01 Vaxcyte Inc Methods for the distillation of polysaccharides and their polypeptide conjugates
WO2023034932A1 (fr) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilisation de compositions de vaccin à adjuvant et leur utilisation
US20250057873A1 (en) * 2021-12-16 2025-02-20 Tokyo University Of Science Foundation Intestinal Tumor Suppressor, PGE2 Production Inhibitor, and IL-22BP Production Promoter
CA3247998A1 (fr) * 2022-01-13 2023-07-20 Pfizer Inc. Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023161817A1 (fr) * 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
US20250302937A1 (en) * 2022-04-08 2025-10-02 St. Jude Children's Research Hospital Immunogenic compositions and methods for reducing transmission of pathogens
WO2024110827A1 (fr) * 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
JP7804631B2 (ja) * 2022-11-22 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
CN120380161A (zh) * 2022-12-31 2025-07-25 康码（上海）生物科技有限公司 一种用于插入非天然氨基酸的体外无细胞蛋白质合成体系、方法及应用
WO2024166008A1 (fr) * 2023-02-10 2024-08-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2025093628A1 (fr) 2023-10-31 2025-05-08 Valanx Biotech Gmbh Protéines synthétiques antigéniques contenant un acide tétrazine-aminé

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510606A1 (fr) 1981-07-30 1983-02-04 Berri Balzac Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
WO1988010130A1 (fr) 1987-06-19 1988-12-29 Terumo Kabushiki Kaisha Instrument medical et production de cet instrument
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
AU634153B2 (en) 1988-02-01 1993-02-18 Wyeth Holdings Corporation T-cell epitope as carriers molecule for conjugate vaccines
CA2059692C (fr) 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
PT616034E (pt) 1993-03-05 2005-02-28 Wyeth Corp Plasmideo para a producao de proteina crm e toxina da difteria
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US6994986B2 (en) 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
JP2001190665A (ja) 2000-01-14 2001-07-17 Terumo Corp シリンジ
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US7041479B2 (en) 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
US6548276B2 (en) 2000-09-06 2003-04-15 The Board Of Trustees Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
CA2428693A1 (fr) 2000-11-14 2002-05-23 The Board Of Trustees Of The Leland Stanford Junior University Synthese in vitro de proteines utilisant des intermediaires glycolytiques comme source d'energie
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2003259912B2 (en) 2002-08-19 2008-10-23 The Board Of Trustees Of The Leland Stanford Junior University Improved methods of in vitro protein synthesis
CA2500653A1 (fr) 2002-10-16 2004-04-29 The Scripps Research Institute Synthese de glycoproteines
JP2006506989A (ja) 2002-11-07 2006-03-02 シナジー アメリカ，インコーポレイテッド 肺炎球菌感染を治療または予防するための組成物および方法
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
PT1601689E (pt) 2003-03-13 2008-01-04 Glaxosmithkline Biolog Sa Processo de purificação para citolisina bacteriana
US7341852B2 (en) 2003-07-18 2008-03-11 The Board Of Trustees Of The Leland Stanford Junior University Methods of decoupling reaction scale and protein synthesis yield in batch mode
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US9410170B2 (en) 2003-11-20 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vitro protein synthesis
ES2394443T3 (es) 2004-03-25 2013-01-31 The Board Of Trustees Of The Leland Stanford Junior University Mejora del rendimiento en la expresión de proteínas en sistemas de síntesis de proteínas en ausencia de células mediante la adición de agentes antiespumantes
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1866342B1 (fr) 2005-04-08 2018-11-21 Wyeth LLC Separation de contaminants a partir de polysaccharide de streptococcus pneumoniae par manipulation du ph
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102378962B1 (ko) 2005-04-08 2022-03-28 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
US7312049B2 (en) 2005-06-14 2007-12-25 The Board Of Trustees Of The Leland Stanford Junior University Total amino acid stabilization during cell-free protein synthesis
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2621023C (fr) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Vaccination multiple comprenant des meningocoques du serogroupe c
US8183010B2 (en) 2005-10-31 2012-05-22 The Board Of Trustees Of The Leland Stanford Junior University Cell-free synthesis of membrane bound polypeptides
CN103251940A (zh) 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 疫苗
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2006336520B2 (en) 2005-12-28 2011-09-15 The Uab Research Foundation Pneumococcal serotypes
US8481054B2 (en) 2005-12-28 2013-07-09 The UAB Foundation Pneumococcal serotypes
DE102006002417A1 (de) 2006-01-18 2007-07-19 Kaindl Flooring Gmbh Verfahren zur Herstellung eines Verkleidungselements
CA2644724C (fr) 2006-03-17 2016-05-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procede de preparation de conjugues immunogeniques multivalents complexes
EP2007427A4 (fr) 2006-04-11 2012-04-04 Yeda Res & Dev Vaccins ameliores comprenant des supports peptidiques multimeres derives de la hsp60
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2035554B1 (fr) 2006-06-29 2013-04-24 The Board of Trustees of The Leland Stanford Junior University Synthese acellulaire de proteines contenant des acides amines non naturels
EP2044194B1 (fr) 2006-06-30 2011-10-05 University Of Georgia Research Foundation, Inc. Hydrates de carbone d'anthrax, leur synthèse et leur utilisation
EP2056871B1 (fr) 2006-08-07 2017-11-15 President and Fellows of Harvard College Vaccins à base de matrice protéique et procédés de fabrication et d'administration de tels vaccins
CN102648979B (zh) 2006-10-10 2014-05-14 惠氏公司 肺炎链球菌3型多糖的纯化
EP2433648A3 (fr) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccin comprenant une émulsion adjuvante huile en l'eau
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EP2109682A4 (fr) 2007-01-18 2012-05-09 Univ Leland Stanford Junior Synthèse acellulaire améliorée de protéines actives contenant des liaisons bisulfure
PL2436700T3 (pl) 2007-03-23 2018-12-31 Wyeth Llc Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
EP2222341B1 (fr) 2007-11-21 2015-02-25 University Of Georgia Research Foundation, Inc. Alcynes et procédés de réaction d'alcynes avec des composés dipolaires-1,3 fonctionnels
WO2009106085A1 (fr) 2008-02-28 2009-09-03 Nordic Vaccine A/S Compositions vaccinales comprenant des antigènes saccharidiques
KR101695800B1 (ko) 2008-03-05 2017-02-22 사노피 파스퇴르 항원보강제 함유 백신 조성물의 안정화 방법
CN102257155B (zh) 2008-12-18 2016-03-02 惠氏有限责任公司 控制肺炎链球菌血清型19a多糖分子量的方法
AU2009335824B2 (en) 2008-12-18 2013-07-04 Wyeth Llc Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon
JP5798489B2 (ja) 2009-01-12 2015-10-21 ストロ バイオファーマ， インコーポレイテッド インビトロタンパク質合成システムを用いて非天然アミノ酸をタンパク質に選択的に導入するためのモノチャージシステム
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
IT1398927B1 (it) * 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
US9649372B2 (en) 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2011212183A (ja) 2010-03-31 2011-10-27 Terumo Corp プレフィルドシリンジ
WO2011130544A2 (fr) 2010-04-14 2011-10-20 Sutro Biopharma, Inc. Surveillance d'un système dynamique par chromatographie liquide - spectrométrie de masse
EP3170508B1 (fr) 2010-06-04 2019-11-13 Wyeth LLC Formulations vaccinales
US8912322B2 (en) 2010-07-29 2014-12-16 University Of Georgia Research Foundation, Inc. Aza-dibenzocyclooctynes and methods of making and using same
EP2621905B1 (fr) 2010-09-27 2017-04-12 University Of Georgia Research Foundation, Inc. Procédés comprenant des composés à fonction 1,3-dipôle latents et matériaux préparés par ces procédés
AR084158A1 (es) 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
EP2966061B1 (fr) 2011-03-04 2017-05-03 Life Technologies Corporation Composés et procédés de conjugaison de biomolécules
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
AU2012253359B2 (en) 2011-05-11 2017-06-08 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
WO2012163289A1 (fr) 2011-06-01 2012-12-06 厦门大学 Protéine de fusion comprenant le mutant non toxique de la toxine diphtérique crm197 ou un fragment de celui-ci
US8910915B2 (en) 2011-06-21 2014-12-16 Otter Products, Llc Folding stand and cover
CA2840409A1 (fr) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Utilisation de sortases pour installer des attaches de chimie click pour la ligature de proteine
EP2729178A1 (fr) 2011-07-08 2014-05-14 Novartis AG Procédé de ligature de la tyrosine
US20140294930A1 (en) 2011-08-04 2014-10-02 The Regents Of The University Of California STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
HUE049531T2 (hu) 2012-08-16 2020-10-28 Pfizer Glikokonjugációs eljárások és kompozíciók
SG11201501464TA (en) 2012-08-31 2015-03-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
CN102861326A (zh) 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CA2885625A1 (fr) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Conjugues saccharidiques non lineaires
JP6421122B2 (ja) 2012-10-12 2018-11-07 ストロ バイオファーマ， インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
JP2016501550A (ja) 2012-12-27 2016-01-21 グリコヴァキシン アーゲー Ｃｒｍ１９７に関する方法及び組成物
GB201300707D0 (en) 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
JP6400672B2 (ja) 2013-03-25 2018-10-03 クリスタル ファーマ エセ．ア．ウ． アルカフタジンの製造方法
SG10202108497TA (en) 2013-04-19 2021-09-29 Sutro Biopharma Inc Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
EP3004062B1 (fr) 2013-05-24 2017-07-19 SynAffix B.V. Composés azadibenzocyclooctyne substitués et leur utilisation dans des réactions « click » sans métal
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
DK3055321T3 (en) * 2013-10-11 2018-12-17 Sutro Biopharma Inc Non-natural amino acid tRNA synthetases for para-methylazido-1-phenylalanine
WO2015054658A1 (fr) * 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
US9988619B2 (en) 2013-10-11 2018-06-05 Sutro Biopharma, Inc. Non-natural amino acid tRNA synthetases for pyridyl tetrazine
MX371453B (es) 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3206112A1 (fr) 2014-01-21 2015-07-30 Pfizer Inc. Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues et leurs utilisations
JP6612260B2 (ja) 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート
EP3097080A1 (fr) 2014-01-24 2016-11-30 SynAffix B.V. Procédé de cycloaddition d'un composé 1,3-dippole halogéné avec un (hétéro)cycloalkyne
EP3097079B1 (fr) 2014-01-24 2021-05-12 SynAffix B.V. Procédé de cycloaddition d'un composé hétéro(aryl) 1,3-dipôle avec un (hétéro)cycloalcyne
JP2017510290A (ja) 2014-01-31 2017-04-13 フィナ バイオソリューションズ リミテッド ライアビリティ カンパニー Ｃｒｍ１９７および関連タンパク質の発現および精製
US10597664B2 (en) 2014-01-31 2020-03-24 Fina Biosolutions, Llc Expression and purification of CRM proteins and related proteins, and protein domains
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
US10316322B2 (en) 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
JP2017523985A (ja) 2014-08-05 2017-08-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原用担体分子
US10487133B2 (en) 2014-12-19 2019-11-26 Sutro Biopharma, Inc. Codon optimization for titer and fidelity improvement
EP3242931B1 (fr) 2015-01-08 2021-03-31 Sutro Biopharma, Inc. Formulations pour la stabilisation d'extraits de cellules bactériennes
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
PE20180460A1 (es) 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos
WO2016205545A1 (fr) 2015-06-17 2016-12-22 The Regents Of The University Of California Modification chimiosélective d'une protéine porteuse à l'aide d'un agent cargo marqué par un alcyne contraint
US20160370376A1 (en) 2015-06-17 2016-12-22 Andrei POLUKHTIN Compounds and methods for detection and isolation of biomolecules
ES2857474T3 (es) 2015-06-23 2021-09-29 Biological E Ltd Vacuna conjugada neumocócica multivalente
EP3325008B1 (fr) 2015-07-21 2025-09-10 Pfizer Inc. Compositions immunogènes contenant des antigènes saccharidiques capsulaires conjugués, kits comprenant ces compositions et leurs utilisations
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (fr) 2015-11-20 2017-05-26 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
AU2016392719A1 (en) 2016-02-10 2018-08-02 Pfizer Inc. Therapeutic nanoparticles having EGFR ligands and methods of making and using same
US20190070287A1 (en) 2016-02-12 2019-03-07 Virtici, Llc Tolerance therapeutic for treating polypeptide induced immune activation
EP4488286A3 (fr) 2016-03-31 2025-04-02 Pogona, Llc Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3269385A1 (fr) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugués de polysaccharide-protéine pneumococcique
EP3296741B1 (fr) 2016-09-14 2019-08-21 Serum Institute of India Private Limited Essai à base de billes multiplexes pour la quantification de plusieurs types de protéines porteuses dans une composition vaccinale conjuguée multivalente
JP2019529497A (ja) 2016-09-30 2019-10-17 バイオロジカル イー リミテッド 多糖類−タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
DK3562503T3 (da) 2016-12-30 2025-05-26 Vaxcyte Inc Polypeptid-antigen-konjugater med ikke-naturlige aminosyrer
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
WO2018147641A1 (fr) 2017-02-07 2018-08-16 한미약품 주식회사 Composé lieur polymère non peptidique, conjugué comprenant ledit composé lieur, et procédés de préparation desdits composé lieur et conjugué
US20200054740A1 (en) 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
US11219680B2 (en) 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
CA3050120A1 (fr) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Amelioration de l'immunogenicite de conjugues de polysaccharide de streptococcus pneumoniae et de proteine
EP3585427A4 (fr) 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. Procédés d'amélioration de la filtrabilité de réactions de polysaccharide conjugué à une protéine
WO2019050818A1 (fr) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Procédés de formulation de polysaccharides pneumococciques pour conjugaison à une protéine porteuse
AR111781A1 (es) 2017-05-10 2019-08-21 Sanofi Sa Ligadores peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050814A1 (fr) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Polysaccharides antipneumococciques et leur utilisation dans des conjugués immunogènes polysaccharide-protéine porteuse
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019070994A1 (fr) 2017-10-04 2019-04-11 Liffey Biotech Limited Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
US20210177957A1 (en) 2017-12-06 2021-06-17 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN112074293B (zh) 2018-04-30 2025-07-11 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
WO2019212842A1 (fr) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Procédés de production de conjugués protéine porteuse-polysaccharide capsulaire de streptococcus pneumoniae à partir de lyosphères
WO2019220304A1 (fr) 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. Vaccin conjugué de polysaccharide pneumococcique 15-valent

Also Published As

Publication number Publication date
IL267709A (en) 2019-08-29
CN110366428A (zh) 2019-10-22
IL317054A (en) 2025-01-01
AU2025200091A1 (en) 2025-01-30
US11998599B2 (en) 2024-06-04
AU2017388891B2 (en) 2024-10-17
WO2018126229A9 (fr) 2019-07-25
JP7186166B2 (ja) 2022-12-08
MX2019007910A (es) 2019-12-05
CN110366428B (zh) 2024-05-17
ES3024474T3 (en) 2025-06-04
WO2018126229A2 (fr) 2018-07-05
US20240342274A1 (en) 2024-10-17
JP2020504760A (ja) 2020-02-13
PH12019501552A1 (en) 2020-06-01
JP2024109771A (ja) 2024-08-14
EP3562503B1 (fr) 2025-04-23
AU2017388891C1 (en) 2025-04-17
MX2022014980A (es) 2023-01-04
IL267709B2 (en) 2025-04-01
JP7494276B2 (ja) 2024-06-03
DK3562503T3 (da) 2025-05-26
BR112019013475A2 (pt) 2020-02-27
EP3562503A2 (fr) 2019-11-06
EP4588521A2 (fr) 2025-07-23
AU2017388891A1 (en) 2019-07-04
EP4588521A3 (fr) 2025-10-22
CA3048981A1 (fr) 2018-07-05
KR20190103256A (ko) 2019-09-04
IL267709B1 (en) 2024-12-01
JP2023022188A (ja) 2023-02-14
ZA201904307B (en) 2024-10-30
US20180333484A1 (en) 2018-11-22
CN118662649A (zh) 2024-09-20
KR20240110660A (ko) 2024-07-15
WO2018126229A3 (fr) 2018-08-09

Similar Documents

Publication Publication Date Title
MA47223A (fr) Conjugués polypeptide-antigène avec des acides aminés non naturels
IL288461A (en) Targeted nucleic acid conjugate compositions
SI3592393T1 (sl) Sprostljivi konjugati
LT3525830T (lt) Pirolbenzodiazepino konjugatai
MA42134A (fr) Conjugués peptides/oligonucléotides
EP3328394A4 (fr) Arn épitope peptidiques concatémériques
DK3538559T3 (da) Rekombinante pmhc klasse ii-molekyler
EP3430251A4 (fr) Craquage d'ammoniac
EP3325668A4 (fr) Édition de l'adn mitochondrial
LT3723783T (lt) Į mitochondrijas nukreipiami peptidai
EP3355931C0 (fr) Conjugués de protéines
EP3520653A4 (fr) Siège
EP3294281A4 (fr) Supplémentation en acides aminés
HUE064240T2 (hu) Fehérjetisztítás
PT3445743T (pt) Pró-fármaco de derivado de aminoácido
HUE055210T2 (hu) Monometilfumarát prodrug készítmények
DK3544634T3 (da) MET-antistof-lægemiddelkonjugater
EP3538665A4 (fr) Molécules de détection de protéase
MA43685A (fr) Solutions aqueuses d'acides aminés n-acylés
EP3854344C0 (fr) Ensemble de fixation dentaire
EP3624829A4 (fr) Injection d'octréotide
DK3448879T3 (da) Claudin-6 peptider
EP3495200A4 (fr) Siège
FI20165515A7 (fi) Muunneltuja dekstraanikonjugaatteja
IL262907B1 (en) Use of an amino sugar as plasticizer